Sublingual buprenorphine is effective in the treatment of chronic pain syndrome

American Journal of Therapeutics

Volumn 12, Issue 5, 2005, Pages 379-384

  Malinoff, Herbert L ^a   Barkin, Robert L ^b,c   Wilson, Geoffrey ^a  

^a Pain/Recovery Solutions   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c North Shore Cardiologists   (United States)

Author keywords

Buprenorphine; Chronic pain; Detoxification; Treatment

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; NARCOTIC ANALGESIC AGENT; OPIATE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHENIA; ATAXIA; BRONCHOSPASM; CHRONIC PAIN; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DIAPHORESIS; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INSOMNIA; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIOSIS; MOOD; NAUSEA; OPIATE ADDICTION; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RIGOR; SEDATION; SIDE EFFECT; TREATMENT FAILURE; VASODILATATION; VOMITING; WITHDRAWAL SYNDROME;

ADMINISTRATION, SUBLINGUAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN;

EID: 26844568733     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000160935.62883.ff     Document Type: Article

References (32)

1. Chae H, Audette J. Chronic pain syndrome. In: Frontera W, ed. Essentials of Physical Medicine and Rehabilitation. Philadelphia: Hanley and Belfus; 2002:511-516.
2. Keefe FJ, Rumble ME, Scipio CD, et al. Psychological aspects of persistent pain: current state of the science. J Pain. 2004;5:195-211.
3. Sees KL. Opioid use in the treatment of chronic pain: assessment of addiction. J Pain Symptom Manage. 1993;8: 257-264.
4. Chavkin C, McLaughlin JP, Celver JP. Regulation of opioid receptor function by chronic agonist exposure. Mol Pharmacol. 2001;60:20-25.
5. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765-1772.
6. Geisser ME, Robinson ME, Riley JR. Pain beliefs, coping, and adjustment to chronic pain. Pain Forum. 1999;8:161-168.
7. Hadler NM. Options in disability determination. J Rheumatol. 2002;29:407-410.
8. Craig TK, Boardman AP, Mills K. The South London somatisation study. Br J Psychiatry. 1993;163:579-588.
9. Craig TK, Drake H. The South London somatisation study II. Br J Psychiatry. 1994;165:248-258.
10. Unruh AM. Gender variations in clinical pain experience. Pain. 1996;65:123-167.
11. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953.
12. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100: 213-217.
13. Nedeljkovic SS, Wasan A, Jamison RN. Assessment of efficacy of long-term opioid therapy in pain patients with substance abuse potential. Clin J Pain. 2002;18:S39-S51.
14. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70:S13-S27.
15. Tejwani GA. The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat. Anesth Analg. 2002;94:1542-1546.
16. Pickworth WB, Johnson RE, Holicky BA, et al. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther. 1993;53:570-576.
17. Bullingham RES, McQuay HJ, Moore RA. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin Pharmacokinet. 1983;8:332-343.
18. Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12:577-581.
19. Gueye PN, Megarbane B, Borron SW, et al. Trends in opiate and opioid poisonings in addicts in northeast Paris and suburbs, 1995-99. Addiction. 2002;97:1295-1304.
20. Lintzeris N, Bell J, Bammer G, et al. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction. 2002;97:1395-1404.
21. Heit HA. Dear DEA. J Pain. 2004;(5):303-308.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (Text Revision). Washington, DC: American Psychiatric Association; 2004.
23. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70:S59-S77.
24. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003;70:S29-S37.
25. Spreekmeester E, Rochford J. Selective mu and delta, but not kappa, opiate receptor antagonists inhibit the habituation of novelty-induced hypoalgesia in the rat. Psychopharmacology (Berl). 2000;148:99-105.
26. Richards ML, Sadée W. Buprenorphine is an antagonist at the κ opioid receptor. Pharm Res. 1985;2:178-181.
27. Villiger JW, Taylor KM. Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci. 1981;29:2699-2708.
28. Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med. 2004;43:580-584.
29. Uhl GR, Sora J, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A. 1999;96:7752-7755.
30. Fields HL. Sources of variability in the sensation of pain. Pain. 1988;33:195-200.
31. Valat JP, Goupille P, Vedere V. Low back pain: risk factors for chronicity. Rev Rheum Engl Ed. 1997;64:189-194.
32. Drug Enforcement Administration (DEA). Department of Justice, Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III - final rule. Fed Regis. 2002;67:62354-62370.